Citations

Clear

6273 citation(s) found for "To, Andrew".

The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints
Tapper, Elliot B. , Goldberg, David S. , Parikh, Neehar D. , Welch, Nicole , Hameed, Bilal , Khalili, Mandana , Stolz, Andrew , Verna, Elizabeth C. , Brown, Robert S., VanWagner, Lisa B. , Moylan, Cynthia A. , Diehl, Anna Mae , Jones, Patricia D. , Shah, Vijay H. , Bajaj, Jasmohan S. , Group, for the LCN Study, Goldberg, David , Welch, Nicole , Khalili, Mandana , Stolz, Andrew , Sanyal, A J , VanWagner, Lisa B , Ladner, Daniela P , Moylan, Cynthia A , Jones, Patricia D , Loomba, Rohit , Simonetto, Douglas A , Bajaj, Jasmohan S , Parikh, Neehar D , Terrault, Norah A. , Sharpton, Suzanne R. , Brown, Robert S., Sanyal, Arun J. , Ladner, Daniela P. , Loomba, Rohit , Dasarathy, Srinivasan , Simonetto, Douglas A. , Group, for the LCN Study

Mayo Clinic

American Journal of Gastroenterology | July 17, 2024 | Volume: 120 | Issue: 3 | Pages: 570-575

10.14309/ajg.0000000000002953 | PMID 39018024 Get It

INTRODUCTION: One of the primary goals of the Liver Cirrhosis Network (LCN) is to develop a cohort study to better understand and predict the risk of hepatic decompensation and other clinical and patient-reported outcomes among patients with Child A cirrhosis. METHODS: The LCN consists of a Scientific Data Coordinating Center and 10 clinical centers whose investigators populate multiple committees. The LCN Definitions and Measurements Committee developed preliminary definitions of cirrhosis and its complications by literature review, expert opinion, and reviewing definition documents developed by other organizations. The Cohort Committee developed the study protocol with the input of the steering committee. RESULTS: The LCN developed a prospective cohort study to describe and predict the rates of incident clinical events pertaining to first decompensation and patient-reported outcomes. The LCN developed a pragmatic definition of compensated cirrhosis incorporating clinical, laboratory, imaging, and histological criteria. Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma were also codified. DISCUSSION: The LCN Cohort Study design will inform the natural history of cirrhosis in contemporary patients with compensated cirrhosis. The LCN Definitions and Measures Committee developed criteria for the definition of cirrhosis to standardize entry into this multicenter cohort study and standardized criteria for liver-related outcome measures. This effort has produced definitions intended to be both sensitive and specific as well as easily operationalized by study staff such that outcomes critical to the LCN cohort are identified and reported in an accurate and generalizable fashion. REGISTRATION: NCT05740358.
Pulsatility of Pulmonary Artery Waveforms Before and After Left Ventricular Assist Device Is Associated With Right Ventricular Failure
Rosenbaum, Andrew , Behfar, Atta , Rossman, Timothy, Lundgren, Scott , Rosenbaum, Andrew N , Rossman, Timothy L, Lundgren, Scott W , Behfar, Atta

Mayo Clinic

ASAIO Journal | July 16, 2024 | Volume: 71 | Issue: 3 | Pages: e38-e40

10.1097/mat.0000000000002272 | PMID 39023937 Get It

Update in the management of gastroenteropancreatic neuroendocrine tumors
Sedlack, Andrew J. H. , Naimian, Amirkia, Hallet, Julie , Halfdanarson, Thor, Capdevilla, Jaume, Rivero, Jaydira Del , Hallet, Julie , Del Rivero, Jaydira , Varghese, Diana Grace , Anari, Pouria Yazdian , Bodei, Lisa , Riechelmann, Rachel P.

Mayo Clinic

Cancer | July 16, 2024 | Volume: 130 | Issue: 18 | Pages: 3090-3105

10.1002/cncr.35463 | PMID 39012928 Get It

Abstract Neuroendocrine neoplasms are a diverse group of neoplasms that can occur in various areas throughout the body. Well‐differentiated neuroendocrine tumors (NETs) most often arise in the gastrointestinal tract, termed gastroenteropancreatic neuroendocrine tumors (GEP‐NETs). Although GEP‐NETs are still uncommon, their incidence and prevalence have been steadily increasing over the past decades. The primary treatment for GEP‐NETs is surgery, which offers the best chance for a cure. However, because GEP‐NETs are often slow‐growing and do not cause symptoms until they have spread widely, curative surgery is not always an option. Significant advances have been made in systemic and locoregional treatment options in recent years, including peptide‐receptor radionuclide therapy with α and β emitters, somatostatin analogs, chemotherapy, and targeted molecular therapies.
Outcomes of patients with alcohol‐associated hepatitis and acute kidney injury – Results from the HRS Harmony Consortium
T., Ann , Allegretti, Andrew S. , Cullaro, Giuseppe , Ouyang, Tianqui, Asrani, Sumeet K. , Przybyszewski, Eric M. , Robinson, Jevon E., Wadei, Hani M. , Hillien, Shelsea A. St., Saly, Danielle L. , Dageforde, Leigh Anne , Regner, Kevin R. , Belcher, Justin M. , Patidar, Kavish R. , Ma, Ann T , Ufere, Nneka N , Patidar, Kavish R , Asrani, Sumeet K , Wadei, Hani M , Cullaro, Giuseppe , Chung, Raymond T. , Wilechansky, Robert M. , Sharma, Pratima , Simonetto, Douglas A. , Jalal, Prasun K. , Orman, Eric S.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 16, 2024 | Volume: 60 | Issue: 6 | Pages: 778-786

10.1111/apt.18159 | PMID 39010302 Get It

Summary Background & Aims The development of acute kidney injury (AKI) in the setting of alcohol‐associated hepatitis (AH) portends a poor prognosis. Whether the presence of AH itself drives worse outcomes in patients with cirrhosis and AKI is unknown. Methods Retrospective cohort study of 11 hospital networks of consecutive adult patients admitted in 2019 with cirrhosis and AKI. AKI phenotypes, clinical course, and outcomes were compared between AH and non‐AH groups. Results A total of 2062 patients were included, of which 303 (15%) had AH, as defined by National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria. Patients with AH, compared to those without, were younger and had higher Model for End‐stage Liver Disease‐Sodium (MELD‐Na) scores on admission. AKI phenotypes significantly differed between groups ( p < 0.001) with acute tubular necrosis occurring more frequently in patients with AH. Patients with AH reached more severe peak AKI stage, required more renal replacement therapy, and had higher 90‐day cumulative incidence of death (45% [95% CI: 39%–51%] vs. 38% [95% CI: 35%–40%], p = 0.026). Using no AH as reference, the unadjusted sHR for 90‐day mortality was higher for AH (sHR: 1.24 [95% CI: 1.03–1.50], p = 0.024), but was not significant when adjusting for MELD‐Na, age and sex. However, in patients with hepatorenal syndrome, AH was an independent predictor of 90‐day mortality (sHR: 1.82 [95% CI: 1.16–2.86], p = 0.009). Conclusions Hospitalised patients with cirrhosis and AKI presenting with AH had higher 90‐day mortality than those without AH, but this may have been driven by higher MELD‐Na rather than AH itself. However, in patients with hepatorenal syndrome, AH was an independent predictor of mortality.
Impact of an Integrated Human Performance Support Group: Evaluation of Air Force Special Warfare Candidate Training and Musculoskeletal Injury Outcomes Over Eight Fiscal Years
Haydu, Lauren E. , Hogan, Kathleen K, Merseal, Courtney, Feldbrugge, Chase M, Johnson, Andrew S. , Smolka, Michael T, Buse, George J, Carr, Wesley, Butler, Cody R.

Mayo Clinic

Military Medicine | July 13, 2024 | Volume: 190 | Issue: 1-2 | Pages: e251-e258

10.1093/milmed/usae354 | PMID 39002107 Get It

ABSTRACT Introduction The Special Warfare Training Wing and Special Warfare Human Performance Support Group (HPSG; all-co-authors) were established in fiscal year (FY) 2019 to consolidate and oversee all Air Force Special Warfare (AFSPECWAR) training and provide embedded medical and human performance support to candidates with the goal of improving graduation rates and the longevity of the AFSPECWAR operator. The purpose of this manuscript is to assess the impact of the HPSG on AFSPECWAR graduation rates, musculoskeletal injury (MSKI) incidence, and cost. Materials and Methods Graduation rates, MSKI incidence (including incidence density and cumulative incidence probability), and MSKI-related health care costs were assessed across all AFSPECWAR training pipelines spanning 8 FYs 2015–22, including Indoctrination, Assessment, and Selection Courses (Selection); Tactical Air Control Party (TACP); Special Tactics (ST), and Guardian Angel (GA). Results A total of 5,728 distinct candidates were assessed over the time frame. There were significant decreases in attrition when comparing the HPSG era (FY 19–22) with the prior 4-year period for the ST (47% vs. 82% graduates) and TACP (34% vs. 41% graduates) training pipelines. The corresponding Selection (36% graduates) and GA (80% graduates) pipeline attrition rates remained stable. MSKI incidence rates (both incidence density and cumulative incidence probability) overall were not significantly different when comparing the pre-HPSG and HPSG time frames; however, they varied between the two time frames by course. GA candidates had a decrease in MSKI during the apprentice course in the HPSG era compared with the pre-HPSG era (2.4–1.0 cases per 100 trainee weeks; P &lt; .001), which corresponds to a nearly 20% reduction in the cumulative incidence probability (i.e., proportion of trainees injured) after 10 weeks of course. For ST and TACP courses, however, significantly increased incidence of MSKI was observed when comparing the two time frames (P &lt; .001), while for Selection courses, the rates remained stable. A significant reduction in the cost of MSKI-related management (62% total relative value units, 83% total costs) was observed. Conclusion The impact of the HPSG on attrition, MSKI incidence, and cost-of-care was not consistent across all training pipelines; however, taken together, there were no increases in attrition, and the cost of MSKI management was significantly lower.
Risk prediction for clonal cytopenia: multicenter real-world evidence
Xie, Zhuoer , Komrokji, Rami S. , Al‐Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand , Saygin, Caner , Zeidan, Amer M. , Mendez, Lourdes , Coombs, Catherine C. , Madanat, Yazan F. , Chung, Stephen S. , Badar, Talha , Foran, James M. , Tsai, Charlton , Amanam, Idoroenyi , Deeg, H. Joachim , Adès, Lionel, Osman, Afaf E.G. , Dinner, Shira, Chandhok, Namrata S. , Soong, Deborah, Brunner, Andrew M. , Ferrari, Jacqueline, Pozzi, Sara , Padron, Eric , Patnaik, Mrinal M. , Al‐Kali, Aref , Adès, Lionel , Komrokji, Rami S , Mendez, Lourdes , Zeidner, Joshua F , Madanat, Yazan , Badar, Talha , Griffiths, Elizabeth A. , Al Malki, Monzr M , Lai, Catherine , Arana Yi, Cecilia , Osman, Afaf E G , Abaza, Yasmin , Taylor, Justin , Chandhok, Namrata , Carraway, Hetty E. , Elena, Chiara , Gallì, Anna , Patnaik, Mrinal , Malcovati, Luca , Savona, Michael R , Al-Kali, Aref , Patel, Anand , Xie, Zhuoer , Zeidan, Amer M , Bewersdorf, Jan Philipp , Kishtagari, Ashwin , Zeidner, Joshua F. , Desai, Pinkal , Malki, Monzr M. Al , Lai, Catherine , Yi, Cecilia Arana , Abaza, Yasmin , Singh, Abhay , Malcovati, Luca , Savona, Michael R.

Mayo Clinic

Blood | July 12, 2024 | Volume: 144 | Issue: 19 | Pages: 2033-2044

10.1182/blood.2024024756 | PMID 38996210 Get It

Abstract Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 patients with CCUS investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count of &lt;100 × 109/L (score = 2.5), and ≥2 mutations (score = 3). Variable scores were based on the coefficients from the Cox proportional hazards model. This led to the development of the clonal cytopenia risk score (CCRS), which stratified patients into low- (score of &lt;2.5 points), intermediate- (score of 2.5 to &lt;5), and high-risk (score of ≥5) groups. The CCRS effectively predicted 2-year cumulative incidence of MN for low- (6.4%), intermediate- (14.1%), and high-risk (37.2%) groups, respectively, by the Gray test (P &lt; .0001). We further validated the CCRS by applying it to an independent CCUS cohort of 104 patients, demonstrating a c-index of 0.64 (P = .005) in stratifying the cumulative incidence of MN. Our study underscores the importance of integrating clinical and molecular data to assess the risk of CCUS progression, making the CCRS a valuable tool that is practical and easily calculable. These findings are clinically relevant, shaping the management strategies for CCUS and informing future clinical trial designs.
Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig, Thomas E. , Sokol, Lubomir , Kim, Won Seog, Vicente, Fátima de la Cruz , Martı́n, Alejandro , Advani, Ranjana H. , Vidal, Jose Maria Roncero, Navarrete, Raquel De Oña, Izquierdo, Antonia Rodríguez, Domingo‐Doménech, Eva , Saunders, Andrew , Bendris, Nawal , Mackey, J., Leoni, Mollie , Witzig, T.E. , Advani, Ranjana H , Domingo-Domenech, Eva , Sokol, Lubomir , Marín‐Niebla, Ana , Terol, María José , Foss, Francine M. , García-Sancho, Alejandro Martín , Foss, Francine

Mayo Clinic

Blood Advances | July 11, 2024 | Volume: 8 | Issue: 17 | Pages: 4581-4592

10.1182/bloodadvances.2024012806 | PMID 38991123 Get It

Abstract A phase 2, international, open-label, nonrandomized, single-arm trial was conducted to evaluate the efficacy and safety of tipifarnib, a farnesyltransferase inhibitor, as monotherapy for relapsed/refractory peripheral T-cell lymphoma (PTCL) and to evaluate tumor mutation profile as a biomarker of response. Adults with relapsed/refractory PTCL received tipifarnib 300 mg orally twice daily for 21 days in a 28-day cycle. The primary end point was objective response rate (ORR); secondary end points included ORR, progression-free survival (PFS), duration of response (DOR), and adverse events (AEs) in specific subtypes. Sixty-five patients with PTCL were enrolled: n = 38 angioimmunoblastic T-cell lymphoma (AITL), n = 25 PTCL not otherwise specified, and n = 2 other T-cell lymphomas. The ORR was 39.7% (95% confidence interval [CI], 28.1-52.5) in all patients and 56.3% (95% CI, 39.3-71.8) for AITL. Median PFS was 3.5 months overall (954% CI, 2.1-4.4), and 3.6 months (95% CI, 1.9-8.3) for AITL. Median DOR was 3.7 months (95% CI, 2.0-15.3), and greatest in patients with AITL (7.8 months; 95% CI, 2.0-16.3). The median overall survival was 32.8 months (95% CI, 14.4 to not applicable). Tipifarnib-related hematologic AEs were manageable and included neutropenia (43.1%), thrombocytopenia (36.9%), and anemia (30.8%); other tipifarnib-related AEs included nausea (29.2%) and diarrhea (27.7%). One treatment-related death occurred. Mutations in RhoA, DNMT3A, and IDH2 were seen in 60%, 33%, and 27%, respectively, in the AITL tipifarnib responder group vs 36%, 9%, and 9% in the nonresponder group. Tipifarnib monotherapy demonstrated encouraging clinical activity in heavily pretreated relapsed/refractory PTCL, especially in AITL, with a manageable safety profile. This trial was registered at www.ClinicalTrials.gov as #NCT02464228.
Multicenter Study on Physician-Modified Endografts for Thoracoabdominal and Complex Abdominal Aortic Aneurysm Repair
Tsilimparis, Nikolaos , Melo, Ryan Gouveia e , Scali, Salvatore T. , Mendes, Bernardo C. , Han, Sukgu M. , Schermerhorn, Marc L. , Adam, Donald J., Malas, Mahmoud B. , Starnes, Benjamin W., Branzan, Daniela , Timaran, Carlos H. , Bertoglio, Luca , Pedro, Luís Mendes , Pyun, Alyssa J., Magee, Gregory A. , Swerdlow, Nicholas J. , Juszczak, Maciej , Patel, Rohini J. , Panuccio, Giuseppe , Sweet, Matthew P. , Becquemin, J.-P. , Canonge, Jennifer , Porras-Colón, Jésus , Giordano, Antonino , Gouveia E Melo, Ryan , Tenorio, Emanuel R , Scali, Salvatore , Mendes, Bernardo, Han, Sukgu , Schermerhorn, Marc , Farber, Mark , Kolbel, Tilo , Joseph, George , Branzan, Daniela , H Timaran, Carlos , Cieri, Enrico , Verzini, Fabio , Beck, Adam W , Chait, Jesse , Pyun, Alyssa , Magee, Gregory A , Juszczak, Maciej , Barleben, Andrew R. , Patel, Rohini , Panuccio, Giuseppe , Sweet, Matthew P , Zettervall, Sara L , Becquemin, Jean-Pierre , Canonge, Jennifer , Porras-Colón, Jésus , Dias-Neto, Marina , Giordano, Antonino , Oderich, Gustavo S , Tenorio, Emanuel R. , Kölbel, Tilo , Cochennec, Frédéric , Gomes, Vivian Carla , Dias‐Neto, Marina , Oderich, Gustavo S.

Mayo Clinic

Circulation | July 11, 2024 | Volume: 150 | Issue: 17 | Pages: 1327-1342

10.1161/circulationaha.123.068587 | PMID 38989565 Get It

BACKGROUND: Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. METHODS: An international multicenter single-arm cohort study was performed analyzing the outcomes of PMEGs in the treatment of elective, symptomatic, and ruptured complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms. Variables and outcomes were defined according to the Society for Vascular Surgery reporting standards. Device modification and procedure details were collected and analyzed. Efficacy outcomes included technical success and safety outcomes included major adverse events and 30-day mortality. Follow-up outcomes included reinterventions, endoleaks, target vessel patency rates and overall and aortic-related mortality. Multivariable analysis was performed aiming at identifying predictors of technical success, 30-day mortality, and major adverse events. RESULTS: Overall, 1274 patients were included in the study from 19 centers. Median age was 74 (IQR, 68–79), and 75.7% were men; 45.7% were complex abdominal aortic aneurysms, and 54.3% were thoracoabdominal aortic aneurysms; 65.5% patients presented electively, 24.6% were symptomatic, and 9.9% were ruptured. Most patients (83.1%) were submitted to a fenestrated repair, 3.6% to branched repair, and 13.4% to a combined fenestrated and branched repair. Most patients (85.8%) had ≥3 target vessels included. The overall technical success was 94% (94% in elective, 93.4% in symptomatic, and 95.1% in ruptured cases). Thirty-day mortality was 5.8% (4.1% in elective, 7.6% in symptomatic, and 12.7% in ruptured aneurysms). Major adverse events occurred in 25.2% of cases (23.1% in elective, 27.8% in symptomatic, and 30.3% in ruptured aneurysms). Median follow-up was 21 months (5.6–50.6). Freedom from reintervention was 73.8%, 61.8%, and 51.4% at 1, 3, and 5 years; primary target vessel patency was 96.9%, 93.6%, and 90.3%. Overall survival and freedom from aortic-related mortality was 82.4%/92.9%, 69.9%/91.6%, and 55.0%/89.1% at 1, 3, and 5 years. CONCLUSIONS: PMEGs were a safe and effective treatment option for elective, symptomatic, and ruptured complex aortic aneurysms. Long-term data and future prospective studies are needed for more robust and detailed analysis.
Training and Verification Requirements for Interpretation of Cardiac CT and MRI: AJR Expert Panel Narrative Review
Morris, Michael F. , Ocazionez-Trujillo, Daniel , Ordovás, Karen , Ranganath, Praveen , Vargas, Daniel , Woodard, Pamela K. , Choi, Andrew , Rajiah, Prabhakar Shantha, Rajiah, Prabhakar , Budoff, Matthew J. , Ghoshhajra, Brian , Patel, Amit R.

Mayo Clinic

American Journal of Roentgenology | July 10, 2024 | Volume: 224 | Issue: 3 | Pages: No page available

10.2214/ajr.24.31524 | PMID 38984783 Get It

Fibula Free Flap Reconstruction of Cervical Spine Defects: A Multi‐Institutional Study
Yang, Sara , Morton, Zoey , Colcord, Maddie, Moore, Eric J. , Thuener, Jason E. , Bewley, Arnaud F. , Coughlin, Andrew, Richmon, Jeremy D. , Pipkorn, Patrik , Zender, Chad , Wax, Mark K. , Moore, Eric J , Thuener, Jason , Richmon, Jeremy D , Zender, Chad A , Wax, Mark K , Jackson, Ryan S. , Khariwala, Samir S , Winters, Ryan D. , Militsakh, Oleg N. , III, James M. Wright

Mayo Clinic

The Laryngoscope | July 10, 2024 | Volume: 134 | Issue: 12 | Pages: 4923-4928

10.1002/lary.31625 | PMID 38984420 Get It

IntroductionCervical spine defects result in spinal instability, putting the spinal cord and vertebral arteries at risk of damage and possibly devastating neurological injuries. The fibula free flap can span the spinal defects for stability. There is a paucity of literature on this technique.MethodMulti‐institutional retrospective case series reviewing patients who underwent cervical spine reconstruction with a fibula free flap. Patient demographic information, comorbidities, characteristics of cervical spine defects, and free flap complications were collected.ResultsA total of 1187 fibula free flaps across 10 different institutions were reviewed. Thirteen patients (1.09%) underwent cervical spine reconstruction with a fibula free flap. Average age was 52.3 years old with an age range of 12–79 years. There were six males (46.1%) and seven females (53.8%). The most common defect etiology was infection (n = 6, 46.1%). Most commonly involved cervical spine level of the defect was C5 (n = 10) followed by C6 (n = 9) and C4 (n = 8). The majority of reconstructed defects spanned three or more cervical levels, (n = 9, 69.2%). Facial artery was the most common arterial anastomosis (n = 8). Eight patients (61.5%) required a tracheostomy during their postoperative course. None of the patients had symptomatic or radiographic nonunion.ConclusionThis case series demonstrates that a vascularized fibula flap is a potential reconstructive option for cervical spine defects, especially in defects greater than three cervical levels, in the setting of infection, and previously radiated patients.Level of Evidence4 Laryngoscope, 134:4923–4928, 2024